Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections

BioDrugs

Volumn 18, Issue 1, 2004, Pages 9-22

  Netea, Mihai G ^a   Kullberg, Bart Jan ^a   Van Der Meer, Jos W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; HEMOPOIETIC GROWTH FACTOR; INFLIXIMAB; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROLIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGRANULOCYTOSIS; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CROHN DISEASE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; FUNGUS; GENE THERAPY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HOST; HUMAN; IMMUNOMODULATION; LEPROMATOUS LEPROSY; MORTALITY; MYCOBACTERIUM FORTUITUM; MYCOSIS; PRIORITY JOURNAL; PSEUDOMONAS; RECEPTOR DOWN REGULATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANIMALS; BACTERIAL INFECTIONS; CYTOKINES; HUMANS; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; MYCOSES; RECOMBINANT PROTEINS;

EID: 1242341392     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418010-00002     Document Type: Review

References (241)

1. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42
2. Lynn WA, Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 1995; 20: 143-58
3. Shilo M. Non-specific resistance to infection. Annu Rev Microbiol 1959; 13: 255-87
4. Dubos RJ, Schaedler RW. Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections. J Exp Med 1957; 106: 703-17
5. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71
6. Tracey KJ, Fong Y, Hesse D, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4
7. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxin shock by a tumor necrosis factor immunoadhesin. Proc Natl Acad Sci U S A 1991; 88: 10535-9
8. Wakabayashi G, Gelfand JA, Burke JF, et al. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-43
9. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104
10. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-100
11. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-25
12. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52
13. Dinarello CA, Cannon JG, Wolff SM. New concepts on the pathogenesis of fever. Rev Infect Dis 1988; 10: 168-89
14. Van der Meer JW. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1988; 1: 19-25
15. Alexander HR, Doherty GM, Fraker DL, et al. Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice. J Surg Res 1991; 50: 421-4
16. Van der Meer JW, Barza M, Wolff SM, et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci U S A 1988; 85: 1620-3
17. Van't Wout JW, Van der Meer JW, Barza M, et al. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18: 1143-6
18. Dinarello CA, Krueger JM. Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. Fed Proc 1986; 45: 2545-8
19. Cluff LE. Effects of endotoxins on susceptibility to infections. J Infect Dis 1970; 122: 205-15
20. Chedid L, Parant M, Parant F, et al. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A 1977; 74: 2089-93
21. Ozaki Y, Ohashi A, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1 alpha. Infect Immun 1987; 55: 1436-40
22. Minami A, Fujimoto K, Ozaki Y, et al. Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun 1988; 56: 3116-20
23. Morikage T, Mizushima Y, Sakamoto K, et al. Prevention of fatal infections by recombinant human interleukin-1 alpha in normal and anticancer drug-treated mice. Cancer Res 1990; 50: 2099-104
24. Campanile F, Binaglia L, Boraschi D, et al. Antibacterial resistance induced by recombinant interleukin-1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cell Immunol 1990; 128: 250-60
25. Nakamura S, Minami A, Fujimoto K, et al. Combination effect of recombinant human interleukin-1 alpha with antimicrobial agents. Antimicrob Agents Chemother 1989; 33: 1804-10
26. Amura CR, Fontan PA, Sanjuan N, et al. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin Immunol Immunopathol 1994; 73: 261-7
27. Hochepied T, Van Molle W, Berger FG, et al. Involvement of the acute phase protein alphal-acid glycoprotein in nonspecific resistance to a lethal Gram-negative infection. J Biol Chem 2000; 275: 14903-9
28. McIntyre KW, Unowsky J, DeLorenzo W, et al. Enhancement of antibacterial resistance of neutropenic bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun 1989; 57: 48-54
29. Kampschmidt RF, Pulliam LA. Stimulation of antimicrobial activity in the rat with leukocyte endogenous mediator. J Reticuloendothel Soc 1975; 17: 162-9
30. Morrissey PJ, Charrier K. Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium. Infect Immun 1991; 59: 4729-31
31. Morrissey PJ, Charrier K. Treatment of mice with IL-1 before infection increases resistance to a lethal challenge with Salmonella typhimurium: the effect correlates with the resistance allele at the Ity locus. J Immunol 1994; 153: 212-9
32. Leshem B, Dekel R, Bercovier H, et al. Cytokine-induced resistance to microbial infections in normal, immunosuppressed and bone marrow transplanted mice. Bone Marrow Transpl 1992; 9: 471-7
33. Pelkonen S, Pluschke G. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microb Pathog 1989; 6: 415-24
34. Lange JR, Alexander HR, Merino MJ, et al. Interleukin-1 alpha prevention of the lethality of Escherichia coli peritonitis. J Surg Res 1992; 52: 555-62
35. Gladue R, Girard A, Newborg M. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents Actions 1988; 24: 130-6
36. Hebert JC, O'Reilly M, Barry B, et al. Effects of exogenous cytokines on intravascular clearance of bacteria in normal and splenectomized mice. J Trauma 1997; 43: 875-82
37. Shi J, Goodband RD, Chengappa MM, et al. Influence of interleukin-1 on neutrophil function and resistance to Streptococcus suis in neonatal pigs. J Leukoc Biol 1994; 56: 88-94
38. Liu Z, Simpson RJ, Cheers C. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection. Immunology 1995; 85: 562-7
39. Czuprynski CJ, Brown JF. Purified human and recombinant murine interleukin-1 induced accumulation of inflammatory peritoneal neutrophils and mononuclear phagocytes: possible contributions to antibacterial resistance. Microb Pathog 1987; 3: 377-86
40. Czuprynski CJ, Brown JF. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun 1987; 55: 2061-5
41. Kurtz RS, Young KM, Czuprynski CJ. Separate and combined effects of recombinant interleukin-1 alpha and gamma interferon on antibacterial resistance. Infect Immun 1989; 57: 553-8
42. Kullberg BJ, Van't Wout JW, van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319-24
43. Kullberg BJ, Van't Wout JW, Poell RJ, et al. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in mice. Antimicrob Agents Chemother 1992; 36: 1225-9
44. Van der Meer JW, Vogels MT, Kullberg BJ. Interleukin-1 and related proinflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 1994; 7: 161-7
45. Kullberg BJ, Vogels MT, Van der Meer JW. Immunomodulators in bacterial and fungal infections: a review of their therapeutic potential. Clin Immunother 1994; 1: 43-55
46. Porat R, Clark BD, Wolff SM, et al. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 1991; 254: 430-2
47. Vogels MT, Hermsen CC, Huys HL, et al. Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect Immun 1994; 62: 2065-70
48. Vogels MT, Sweep CG, Hermus AR, et al. Interleukin-1-induced nonspecific resistance to bacterial infection in mice is not mediated by glucocorticosteroids. Antimicrob Agents Chemother 1992; 36: 2785-9
49. Stork LC, Peterson VM, Rundus CH, et al. Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol 1988; 16: 163-7
50. Fibbe WE, Van der Meer JW, Falkenburg JH, et al. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp Hematol 1989; 17: 805-8
51. Rogers HW, Tripp CS, Schreiber RD, et al. Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994; 153: 2093-101
52. Kullberg BJ, Van't Wout JW, van Furth R. No effect of recombinant human interleukin-1 on numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991; 15: 457-70
53. Georgilis K, Schaefer C, Dinarello CA, et al. Human recombinant interleukin 1 beta has no effect on intracellular calcium or on functional responses of human neutrophils. J Immunol 1987; 138: 3403-7
54. Vogels MT, Van Rooyen N, Bemelmans MHA, et al. Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of macrophage and soluble TNF receptors. In: Mechanisms of enhanced natural resistance to infection induced by interleukin-1. Nijmegen: Catholic Unversity Nijmegen, 1994: 117-34
55. Langermans JA, Van der Hulst ME, Nibbering PH, et al. IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor alpha. J Immunol 1992; 148: 568-74
56. Cheers C, Zhan YF, Egan PJ. In vivo IL-1 potentiates both specific and non-specific arms of immune reponse to infection. Immunology 1990; 70: 411-3
57. Hunter CA, Chizzonite R, Remington JS. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. J Immunol 1995; 155: 4347-54
58. Vogels MTE, Cantoni L, Carelli M, et al. Role of acute phase proteins in interleukin-1-induced resistance to bacterial infection in mice. Antimicrob Agents Chemother 1993; 37: 2527-33
59. Van der Meer JW, Helle M, Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 in nonspecific resistance to infection. Eur J Immunol 1989; 19: 413-6
60. Vogels MT, Lindley IJ, Curfs JH, et al. Effects of interleukin-8 on non-specific resistance to infection in neutropenic and normal mice. Antimicrob Agents Chemother 1993; 37: 276-80
61. Vogels MT, Mensink EJ, Ye K, et al. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol 1994; 153: 5772-80
62. Holtmann H, Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin-1 and 4beta-phorbol-12-myristate-13-acetate. J Immunol 1987; 139: 1161-7
63. Beekhuizen H, Corsel-Van Tilburg AJ, Blokland I, et al. Characterization of the adherence of human monocytes to cytokine-stimulated human macrovascular endothelial cells. Immunology 1991; 74: 661-9
64. Ulich TR, del Castillo J, Keys M, et al. Kinetics and mechanisms of recombinant human interleukin-1 and tumor necrosis factor alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987; 139: 3406-15
65. Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte macrophage colony-stimulating factor. J Immunol 1988; 140: 108-11
66. White CW, Ghezzi P. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1989; 1: 361-7
67. Brown J, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci U S A 1990; 87: 5026-30
68. Puri RK, Travis WD, Rosenberg SA. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 1989; 49: 969-76
69. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-78
70. Mancuso G, Tomasello F, Migliardo M, et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994; 62: 4997-5003
71. Barton BE, Shortall J, Jackson JV. Interleukin-6 and II protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64: 714-20
72. Jones EY, Stuart DI, Walker NPC. Structure of tumor necrosis factor. Nature 1989; 338: 225-8
73. Vasalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-43
74. Beutler B, Krochin N, Milsark IW, et al. Control of cachexin (tumor necrosis factor) synthesis; mechanisms of endotoxin resistance. Science 1986; 232: 977-80
75. Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4
76. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31
77. van der Poll T, Lowry SF. Tumor necrosis factor and sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3: 1-12
78. Fischer Jr CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318-27
79. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995; 273: 934-41
80. Fischer CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor: Fc fusion protein. N Engl J Med 1996; 334: 1697-702
81. Figari IS, Mori NA, Palladino Jr MA. Regulation of neutrophil migration and superoxide production by recombinant tumor necrosis factors-alpha and -beta: comparison to recombinant imerferon-gamma and interleukin-1 alpha. Blood 1987; 70: 979-84
82. Seow WK, Thong YH, Ferrante A. Macrophage-neutrophil interactions: contrasting effects of the monokines interleukin-1 and tumour necrosis factor (cachectin) on human neutrophil adherence. Immunology 1987; 62: 357-61
83. Steinbeck MA, Roth JA. Neutrophil activation by recombinant cytokines. Rev Infect Dis 1989; 11: 549-68
84. Nacy CA, Meierovics AI, Belosevic M, et al. Tumor necrosis factor alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 1991; 59: 182-4
85. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-9
86. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40
87. Echtenacher B, Falk W, Mannel DN, et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-6
88. Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003-8
89. Netea MG, van Tits LJ, Curfs JH, et al. Increased susceptibility of TNF-alpha lymphotoxin alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 1999; 163 (3): 1498-505
90. Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression. Arthritis Rheum 2003; 48: 1853-7
91. Chen GH, Reddy RC, Newstead MW, et al. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000; 165: 6496-503
92. Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor alpha protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J Clin Invest 1991; 88: 34-9
93. Cross AS, Sadoff JC, Kelly N, et al. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine recombinant interleukin-1 alpha protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021-7
94. Parant F, Tavernier J, Fiers W, et al. Comparative activity of human and murine tumor necrosis factor in toxicity and anti-infectious assays in mice. Microb Pathog 1990; 8: 143-9
95. Nauciel C, Espinasse-Maes F. Role of gamma-interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450-4
96. Nakano Y, Onozuka K, Terada Y, et al. Protective effect of recombinant tumor necrosis factor alpha in murine salmonellosis. J Immunol 1990; 144: 1935-41
97. Morrissey PJ, Charrier K, Vogel SN. Exogenous tumor necrosis factor alpha and interleukin-1 alpha increase resistance to Salmonella typhimurium: efficacy is influenced by the Ity and Lps loci. Infect Immun 1995; 63: 3196-201
98. Blanchard DK, Djeu JY, Klein TW, et al. Protective effect of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol 1988; 43: 429-35
99. Vaudaux P, Grau GE, Huggler E, et al. Contribution of tumor necrosis factor to host defense against staphylococci in a guinea pig model of foreign body infections. J Infect Dis 1992; 166: 58-64
100. Nordmann P, Ronco E, Guenounou M. Involvement of interferon-gamma and tumor necrosis factor alpha in host defense against Rhodococcus equi. J Infect Dis 1993; 166: 58-64
101. Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol 1987; 139: 4225-31
102. Desiderio JV, Kiener PA, Lin FP, et al. Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor. Infect Immun 1989; 57: 1615-7
103. Roll JT, Young KM, Kurtz RS, et al. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology 1990; 69: 316-22
104. van Furth R, van Zwet TL, Buisman AM, et al. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Lisreria monocytogenes in various organs. J Infect Dis 1994; 170: 234-7
105. Sarmento AM, Appelberg R. Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor alpha production in infected mice and in in-vitro mouse macrophages. Infect Immun 1995; 63: 3759-65
106. Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with TL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140: 3006-13
107. Bermudez LE, Stevens P, Kolonoski P, et al. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant 1L-2 and tumor necrosis factor. J Immunol 1989; 143: 2996-3000
108. Williams DM, Magee DM, Bonewald LF, et al. A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun 1990; 58: 1572-6
109. Nagai H, Guo J, Choi H, et al. Interferon-gamma and tumor necrosis factor alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554-60
110. Nakane A, Minagawa T, Kohanawa M, et al. Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance and primary and secondary Lisreria monocytogenes infections. Infect Immun 1989; 57: 3331-7
111. Djeu JY, Blanchard DK, Halkias D, et al. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol 1986; 137: 2980-4
112. Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115-22
113. Sypek JP, Jacobson S, Vorys A, et al. Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages. Infect Immun 1993; 61: 3901-6
114. Mastroeni P, Skepper JN, Hormaeche CE. Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections. Infect Immun 1995; 63: 3674-82
115. Vasquez-Torres A, Fantuzzi G, Edwards CK, et al. Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A 2001; 98: 2561-5
116. Wong GHW, Elwell JH, Oberley LH, et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989; 58: 923-30
117. Dinarello CA, Cannon JG, Wolff SM. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163: 1433-50
118. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Set U S A 1993; 90: 3725-9
119. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85
120. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988; 167: 1511-6
121. Wheelock EF. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149: 310-1
122. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982; 298: 859-64
123. Greenlund AC, Schreiber RD, Goeddel DV, et al. Interferon-gamma induces receptor dimerization in solution and on cells. J Biol Chem 1993; 268: 18103-12
124. Klebanoff SJ, Olszowski S, van Voorhis WC, et al. Effect of gamma-interferon on human neutrophils: protection from deterioration from storage. Blood 1992; 80: 225-33
125. Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97: 459-67
126. Gallin JI, Farber JM, Holland SM, et al. Interferon-gamma in the management of infectious diseases. Ann Intern Med 1995; 123: 216-22
127. Dalton DK, Pitts-Meek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739-42
128. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259: 1742-5
129. Kamijo R, Le J, Shapiro D, et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 178: 1435-40
130. Buchmeier NA, Schreiber RD. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A 1985; 82: 7404-8
131. Langermans JA, Mayanski DM, Nibbering PH, et al. Effect of IFN-gamma and endogenous TNF on the histopathological changes in the liver of Listeria monocytogenes-infected mice. Immunology 1994; 81: 192-7
132. Kiderlen A, Kauffmann HE, Lohmann-Matthes ML. Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur J Immunol 1984; 14: 964-7
133. Langermans JA, van der Hulst ME, Nibbering PH, et al. Intravenous injection of IFN-gamma inhibits the proliferation of Listeria monocytogenes in the liver but not in the spleen and peritoneal cavity. Immunology 1992; 77: 354-61
134. Portnoy DA, Schreiber RD, Connelly P, et al. Gamma-interferon limits access of Lisieria monocytogenes to the macrophage cytoplasm. J Exp Med 1989; 170: 2141-6
135. Tripp CS, Kanagawa O, Unanue ER. Secondary response to Listeria infection requires interferon-gamma but is partially independent of 1L-12. J Immunol 1995; 155: 3427-33
136. Muotiala A, Makela PH. The role of IFN-gamma in murine Salmonella typhimurium infection. Microb Pathog 1990; 8: 135-41
137. Edwards III CK, Hedegard HB, Zlotnik A. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol 1986; 136: 1820-7
138. Khor M, Lowrie DB, Coates AR, et al. Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis. Br J Exp Pathol 1986; 67: 587-96
139. Klein TW, Yamamoto Y, Brown HK, et al. Interferon-gamma induced resistance to Legionella pneumophila in susceptible A/J mouse macrophages. J Leukocyte Biol 1991; 49: 98-103
140. Skerrett SJ, Martin TR. Intratracheal interferon-gamma augments pulmonary defense in experimental legionellosis. Am J Respir Crit Care Med 1994; 149:50-8
141. Canning PC, Roth JA. Effects of in vitro and in vivo administration of recombinant bovine interferon-gamma on bovine neutrophil responses to Brucella abortus. Vet Immunol Immunopathol 1989; 20: 119-33
142. Bohn E, Heesemann J, Ehlers S, et al. Early gamma interferon mRNA expression is associated with resistance of mice against Yersinia enterocolitica. Infect Immun 1994; 62: 3027-33
143. Johansen HK, Hougen HP, Rygaard J, et al. Interferon-gamma treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996; 103: 212-8
144. Hershman MJ, Polk HC, Pietsch JD, et al. Modulation of infection by gamma interferon treatment following trauma. Infect Immun 1988; 56: 2412-8
145. ten Hagen TL, van Vianen W, Bakker-Woudenberg IA. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumonias septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J Infect Dis 1995; 171 (2): 385-92
146. Hershman MJ, Sonnenfeld G, Logan WA, et al. Effect of interferon-gamma treatment on the course of a burn wound infection. J Interferon Res 1988; 8: 367-72
147. Rozalska B, Wadstrom T. Interferon-gamma, interleukin-1, and tumor necrosis factor alpha synthesis during experimental murine staphylococcal infection. FEMS Microbiol Immunol 1993; 7: 145-53
148. Boelens JJ, van der Poll T, Dankert J, et al. Interferon-gamma protects against biomaterial-associated Staphylococcus epidermidis infection in mice. J Infect Dis 2000; 181: 1167-71
149. Byrne GI, Grubbs B, Marshall TJ, et al. Gamma interferon-mediated cytotoxity related to murine Chlamydia trachomatis infection. Infect Immun 1988; 56: 2023-7
150. Kullberg BJ, Van't Wout JW, Hoogstraten C, et al. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436-43
151. Joly V, Saint-Julien L, Carbon C, et al. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170: 1331-4
152. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46: 437-42
153. Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491-4
154. Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol 2001; 38: 903-9
155. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of ThI CD4+ T cells through IL-12 produced by Listerio-induced macrophages. Science 1993; 260: 547-9
156. Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of TNF-alpha. J Immunol 1990; 145: 4290-7
157. Agarwall BB, Eesallu TE, Mass PE. Characterization of receptors for human turnor necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665-8
158. Geertsma MF, Nibbering PH, Pos O, et al. Interferon-gamma-activated human granulocytes kill ingested Mycobacterium fortuitum more efficiently than normal granulocytes. Eur J Immunol 1990; 20: 869-73
159. Gallin JI. Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 1991; 13: 973-8
160. Gallin JI, Malech HL, Melnick DA, et al. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509-16
161. Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease: European follow-up study. Eur J Pediatr 1995; 154: 295-302
162. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 1985; 134: 1619-22
163. Jendrossek V, Peters AMJ, Buth S, et al. Improvement of superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood 1993; 81: 2131-7
164. Muhlebach TJ, Gabay J, Nathan CF, et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. Clin Exp Immunol 1992; 88 (2): 203-10
165. Ezekowitz RAB, Dinauer MC, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146-51
166. Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849-52
167. Weisbart RH, Kwan L, Golde DW, et al. Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to major physiological chemoattractants. Blood 1987; 69: 18-21
168. Nathan CF, Kaplan G, Lewis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6-12
169. Kaplan G, Mathur NK, Job CK, et al. Effect of multiple interferon-gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 1989; 86: 8073-7
170. Samuel NM, Grange JM, Samule S, et al. A study of the effects of intradermal administration of recombinant interferon-gamma in lepromatous leprosy patients. Lepr Rev 1987; 58: 389-96
171. Damasco MH, Sarno EN, Lobao AS, et al. Effect of cutaneous cell-mediated immune response to rIFN gamma on Mycobacterium leprae viability in the lesions of lepromatous leprosy. Braz J Med Biol Res 1992; 25: 457-63
172. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348-52
173. Chatte G, Panteix G, Perrin-Fayolle M, et al. Aerosolized interfeon-gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med 1995; 152: 1094-101
174. Squires KE, Murphy WF, Madoff LC, et al. Interferon-gamma and Mycobacterium avium-intracellular infection. J Infect Dis 1989; 159: 599-607
175. Bermudez LE, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother 1991; 35: 2625-30
176. Dries DJ, Jurkovich GJ, Maie RV, et al. Effect of interferon gamma on infection-related death in patients with severe injuries. Arch Surg 1994; 129: 1031-41
177. Poynton CH, Barnes RA, Rees J. Interferon-gamma and granulocyte- macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239-40
178. Riddell LA, Pinching AJ, Hill S, et al. A phase II study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17: 789-97
179. Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin Infect Dis 1995; 21: 1439-49
180. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-35
181. Cassatella MA, Meda L, Gasperini S, et al. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995; 25: 1-7
182. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76
183. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulating factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-94
184. Ma Y, Seiler KP, Tai K-F, et al. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect Immun 1994; 62: 3663-8
185. Sieling PA, Wang X-H, Gately MK, et al. IL-12 regulates T helper cytokine responses in human infectious disease. J Immunol 1994; 153: 3639-46
186. Zhang M, Gately MK, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733-9
187. Romani L, Bistoni F, Mencacci A, et al. IL-12 in Candida albicans infections. Res Immunol 1995; 146: 532-8
188. Kaufmann SHE. Immunity to intracellular microbial pathogens. Immunol Today 1995; 16: 338-42
189. Greenberger MJ, Kunkel SL, Stricter RM, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996; 157: 3006-12
190. Jiang C, Magee DM, Cox RA. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental cocidioidomycosis. Infect Immun 1999; 67: 2996-3001
191. Wagner RD, Steinberg H, Brown JF, et al. Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection. Microb Pathog 1994; 17: 175-7
192. Gladue PR, Laquerre AM, Magna HA, et al. In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats. Cytokine 1994; 6: 318-23
193. Tripp CS, Gately MK, Hakimi J, et al. Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice: reversal by IFN-gamma. J Immunol 1994; 152: 1883-90
194. Flynn JL, Goldstein MM, Triebold KJ, et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2515-22
195. Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterhtm tuberculosis-infected human monocytes. Cell Immunol 1994; 156: 529-36
196. Kobayashi K, Kasama T, Yamazaki J, et al. Protection of mice from Mycobacteriiim avium infection by recombinant interleukin-12. Antimicrob Agents Chemother 1995; 39: 1369-71
197. Kobayashi K, Yamazaki J, Kasama T, et al. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy. J Infect Dis 1996; 174: 564-73
198. Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun 1995; 63: 4099-104
199. Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995; 63: 4011-5
200. Castro AG, Silva RA, Appelberg R. Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995; 155: 2013-9
201. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428-35
202. Metzger DW, Raeder R, Van Cleave VH, et al. Protection of mice from group A streptococcal skin infection by interleukin-12. J Infect Dis 1995; 171: 1643-5
203. Mastroeni P, Harrison JA, Chabalgoity JA, et al. Effect of interleukin-12 neutralization on host resistance and interferon gamma production in mouse typhoid. Infect Immun 1996; 64: 189-95
204. Bohn E, Autenrieth IB. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ cells. J Immunol 1996; 156: 1458-64
205. Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun 1995; 63: 1387-90
206. Huang J, Wang M-D, Lenz S, et al. IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J Immunol 1999; 162: 2217-26
207. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38: 460-4
208. Romani L, Mencacci A, Tonnetti L, et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 153: 5167-75
209. Romani L, Mencaci A, Cenci E, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158: 5349-56
210. Dinarello CA, Novick D, Puren AJ, et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leuk Biol 1998; 63: 658-64
211. Ye K, Clark BD, Dinarello CA. Interleukin-1 downregulates gene and surface expression of interleukin-1 receptor type 1 by destabilizing its mRNA, whereas interleukin-2 increases its expression. Immunology 1992; 75: 427-34
212. Flesch IEA, Hess JH, Huang S, et al. Early interleukin-12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181: 1615-23
213. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161: 3400-7
214. Chehimi J, Tarr SE, Frank I, et al. Natural killer (NK) cells stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789-95
215. Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994; 94: 2435-42
216. Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFNgamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999; 104: 761-7
217. Novick D, Kim S-H, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127-36
218. Netea MG, Fantuzzi G, Kullberg BJ, et al. Neutralization of interleukin-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000; 164: 2644-9
219. Puren AJ, Fantuzzi G, Gu Y, et al. Interleukin-18 (IFNgamma inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human mononuclear cells. J Clin Invest 1998; 101: 711-21
220. Sugawara I, Yamada H, Kaneko H, et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect Immun 1999; 67: 2585-9
221. Kinjo Y, Kawakami K, Uezu K, et al. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12 p40. J Immunol 2002; 169: 323-9
222. Bohn E, Sing A, Zumbihl R, et al. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160: 299-307
223. Wei X-Q, Leung BP, Niedbala W, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999; 163: 2821-8
224. Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial response to pneumococcal pneumonia. J Immunol 2002; 168: 372-8
225. Huang X, McClellan SA, Barrett RP, et al. IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFN-gamma production. J Immunol 2002; 168: 5756-63
226. Neighbors M, Xu X, Barrat FJ, et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon-gamma production. J Exp Med 2001; 194: 343-54
227. Mastroeni P, Clare S, Khan S, et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun 1999; 67: 478-83
228. Kawakami K, Koguchi Y, Qureshi MH, et al. Reduced host resistance and ThI response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186: 121-6
229. Stuyt RJ, Netea MG, Verschueren I, et al. Role of interleukin-18 in host defense against disseminated Candida albicans infection. Infect Immun 2002; 70: 3284-6
230. Kawakami K, Qureshi MH, Zhang T, et al. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 1997; 159: 5528-34
231. Mencacci A, Bacci A, Cenci E, et al. Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000; 68: 5126-31
232. Ohkusu K, Yoshimoto T, Takeda K, et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun 2000; 68: 2449-56
233. Cai G, Kastelein R, Hunter CA. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000; 68: 6932-8
234. Kim SH, Cho D, Kim TS. Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18. Immunology 2001; 102: 234-41
235. Zhang T, Kawakami K, Qureshi MH, et al. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interteron by natural killer cells. Infect Immun 1997; 65: 3594-9
236. Kawakami K, Qureshi MH, Koguchi Y, et al. Role of TNF in the induction of fungicidal activity of mouse peritoneal exudate cells against Cryptococcus neoformans by IL-12 and IL-18. Cell Immunol 1999; 193: 9-16
237. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase 1 trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907-13
238. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993; 328: 756-61
239. Debs RJ, Fuchs HJ, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res 1990; 50: 375-80
240. Mullerad J, Cohen S, Voronov E, et al. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin-1 via biodegradable microspheres. Cytokine 2000; 12: 1683-90
241. ten Hagen TL, van Vianen W, Savelkoul HF, et al. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidyethanolamine or gamma interferon. Infect Immun 1998; 66 (5): 1962-7